N-desulfated heparin improves concanavalin A-induced liver injury partly through inhibiting T lymphocyte adhesion

Inflammation Research

Volumn 52, Issue 9, 2003, Pages 383-389

  Yuan, L ^a,b   Geng, J G ^c   Xu, Q ^a,b  

^a NANJING UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Adhesion; Con A; Liver injury; Lymphocytes; N desulfated heparin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLLAGEN TYPE 1; CONCANAVALIN A; DIMETHYL SULFOXIDE; FIBRONECTIN; HEPARIN; HEPARIN DERIVATIVE; LACTATE DEHYDROGENASE; LAMININ; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL ADHESION; CELL DEGENERATION; CELL HYPERPLASIA; CELL ISOLATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; IN VITRO STUDY; INHIBITION KINETICS; KUPFFER CELL; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA CELL LINE; LIVER CELL; LIVER HISTOLOGY; LIVER INJURY; LIVER LEVEL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; T LYMPHOCYTE;

ANIMALS; CELL ADHESION; CELL DIVISION; COLLAGEN; CONCANAVALIN A; FEMALE; FIBRONECTINS; HEPARIN; HUMANS; JURKAT CELLS; KINETICS; LAMININ; LIVER; MALE; MICE; SPLEEN; T-LYMPHOCYTES;

EID: 0141630496     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1190-8     Document Type: Article

References (35)

1. Xu Q, Wang R, Jiang JY, Wu FH, Lu JF, Tan P et al. Liver injury model induced in mice by a cellular immunologic mechanism-Delayed-type hypersensitivity-induced liver injury to picryl chloride and phenotype of effector cell. Cell Immunol 1996; 167: 38-43.
2. Tiegs G, Hentschel J, Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. Am J Clin Invest 1992; 90: 196-203.
3. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G. Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of rumor necrosis factor. Hepatology 1995; 21: 190-8.
4. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992; 148: 3210-5.
5. Teixeira MM, Hellewell PG. Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 1993; 110: 1496-500.
6. Giuffrè L, Cordey AS, Monai N, Tardy Y, Schapira M, Spertini O. Monocyte adhesion to activated aortic endothelium: Role of L-selectin and heparin sulfate proteoglycans. J Cell Biol 1997; 136: 945-56.
7. Engelberg H. Heparin, heparin fractions, and the atherosclerotic process. Semin Thromb Hemost 1985; 11: 48-55.
8. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1 beta. Nature (Lond.) 1993; 361: 79-82.
9. Bazzoni G, Beltran Nunez A, Mascellani G, Bianchini P, Dejana E, Del Maschio A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte function. J Lab Clin Med 1993; 121: 268-75.
10. Cerletti C, Rajtar G, Marchi E, de Gaetano G, Bizzozero G. Interaction between glycosaminoglycans, platelets, and leukocytes. Semin Thromb Hemost 1994; 20: 245-53.
11. Thourani VH, Brar SS, Kennedy TP, Thornton LR, Watts JA, Ronson RS et al. Nonanticoagulant heparin inhibits NF-kappa B activation and attenuates myocardial reperfusion injury. Am J Physiol 2000; 278: 2084-93.
12. Morrison AM, Wang P, Chaudry IH. A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during heperdynamic sepsis. Shock 1996; 6: 46-51.
13. Lapierre F, Holme K, Lam L, Tressler RJ, Storm N, Wee J et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 1996; 6: 355-66.
14. Kouretas PC, Kim YD, Cahill PA, Myers AK, To LN, Wang YN et al. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation 1999; 99: 1062-8.
15. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR. Protective effects of heparin or N-acetyl heparin in an in vivo model of myocardial ischemia and reperfusion injury. Cardiovas Res 1995; 29: 629-36.
16. Danishefsky I, Ahrens M, Klein S. Effect of heparin modification on its activity in enhancing the inhibition of thrombin by antithrombin III. Biochim Biophys Acta 1977; 498: 215-22.
17. Sache E, Maillard M, Malazzi P, Bertrand H. Partially N-desulfated heparin as a non-anticoagulant heparin: some physicochemical and biological properties. Thromb Res 1989; 55: 247-58.
18. Bjornsson TD, Schneider DE, Hecht AR. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. J Pharmacol Exp Ther 1988; 245: 804-8.
19. Matzner Y, Marx G, Drexler R, Eldor A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost. 1984; 52: 134-7.
20. Wang JG, Mu JS, Zhu HS, Geng JG. N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo. Inflamm Res 2002; 51: 435-43.
21. Bjornsson TD, Schneider DE, Hecht AR. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition. J Pharmacol Exp Ther 1988; 245: 804-8.
22. Chalupny NJ, Peach R, Hollenbaugh D, Ledbetter JA, Farr AG, Aruffo A. T-cell activation molecule 4-1BB binds to extracellular matrix proteins. Proc Natl Acad Sci USA 1992; 89: 10360-4.
23. Fridman R, Lider O, Naparstek Y, Fuks Z, Vlodavsky I, Cohen IR. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol 1987; 130: 85-92.
24. Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83: 752-6.
25. Watanabe K, Takahashi H, Habu Y, Kamiya-Kubushiro N, Kamiya S, Nakamura H et al. Interaction with heparin and matrix metalloproteinase 2 cleavage expose a cryptic anti-adhesive site of fibronectin. Biochemistry 2000; 39: 7138-44.
26. Hershkoviz R, Schor H, Ariel A, Hecht I, Cohen IR, Lider O et al. Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix. Immunology 2000; 99: 87-93.
27. Cotman SL, Halfter W, Cole GJ. Identification of extracellular matrix ligands for the heparan sulfate proteoglycan agrin. Exp Cell Res 1999; 249: 54-64.
28. Kibler C, Schermutzki F, Waller HD, Timpl R, Muller CA, Klein G. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 1998; 5: 307-23.
29. Martinez-Hernandez A. The hepatic extracellular matrix. I. Electron immunohistochemical studies in normal rat liver. Lab Invest 1984; 51: 57-74.
30. Wolf D, Hallmann R, Sass G, Sixt M, Kusters S, Fregien B et al. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR 1-relevance for concanavalin A-induced hepatitis. J Immunol 2001; 15; 166: 1300-7.
31. Wang L, Brown JR, Varki A, Esko JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 2002; 110: 127-36.
32. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol 1995; 130: 1473-82.
33. Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K et al. Heparin modulates integrin function in human platelets. J Vasc Surg 2001; 33: 587-94.
34. San Antonio JD, Lander AD, Karnovsky MJ, Slayter HS. Mapping the heparin-binding sites on type I collagen monomers and fibrils. J Cell Biol 1994; 125: 1179-88.
35. Sweeney SM, Guy CA, Fields GB, San Antonio JD. Defining the domains of type I collagen involved in heparin- binding and endothelial tube formation. Proc Natl Acad Sci USA 1998; 95: 7275-80.